A longitudinal analysis of plasma using ELISA and proteomic profiling will be conducted in patients with metastatic prostate cancer who have received local therapy for their metastases. This will involve using both previously collected blood samples from participants in the OLI-P, OLI-CR-P, and Poly-CR-P studies (retrospective study component) and actively requesting patients’ consent for blood collection (prospective study component). Samples from each participant will be analyzed at three collection time points.
Blood plasma is obtained via Biocoll density gradient centrifugation together with the isolation of circulating tumor cells (CTCs) and stored at -80°C. Peripheral blood mononuclear cell (PBMC) fractions are collected and either stored at -80°C after erythrocyte lysis, or the CD45-
positive leukocytes are depleted using MACS (Miltenyi). The concentrations of various markers identified in previous experiments (including MMP11) are determined using appropriate methods (e.g., ELISA) in the stored plasma and, where applicable, in the patients’ tumor material.
The plasma samples are used, among other things, for mass spectrometric analysis, which is performed in the project partners’ laboratory at the Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences in Magdalenka (Poland).
The study aims to investigate the dynamic changes in protein expression levels (including MMP11) in existing samples from patients with metastatic prostate cancer, both prior to treatment and following radiation therapy, as well as their correlation with clinical parameters (including the Gleason score, TNM status, PSA level, metastasis location, disease progression, and treatment) to determine the potential of these proteins (including MMP11) as possible prognostic biomarkers and regulators of disease progression and metastasis formation.
In the CampaMET study, three additional blood samples (hereinafter also referred to as “biomaterial”) will be collected from each patient so that subsequent laboratory analyses can examine the blood for the presence of specific proteins and tumor cells, as well as changes in these during treatment. To this end, the blood samples will be analyzed before and after radiation therapy. In addition, the study aims to determine whether there is a correlation between the presence of these proteins and specific clinical parameters, including various test values such as PSA levels, the location of metastases, or disease progression. The goal of these blood analyses is to determine the potential of these proteins as possible prognostic biological factors (so-called biomarkers) as well as potential regulators of tumor progression and metastasis formation.
